Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints
Aclaris Therapeutics, Inc. (ACRS)
Last aclaris therapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
aclaristx.com
Company Research
Source: GlobeNewswire
ATI-502 did not achieve statistical superiority at the primary or secondary endpoints due to high rates of disease resolution in vehicle-treated patients WAYNE, Pa., June 26, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced results from a Phase 2 clinical trial of ATI-502 (AA-201 Topical), an investigational topical Janus Kinase (JAK) 1/3 inhibitor, in patients with alopecia areata (AA). ATI-502 did not achieve statistical superiority at the primary or secondary endpoints due to high rates of disease resolution in vehicle-treated patients. AA-201 Topical, a Phase 2 randomized, double-blinded, parallel-group, vehicle-controlled trial, evaluated the safety, efficacy, and dose response of two concentrations of ATI-502, 0.12% and 0.46%, on the regrowth of hair in 129 subjects with AA. Subjects applied ATI-502 to their scalp twice daily for 24 weeks. The primary endpoi
Show less
Read more
Impact Snapshot
Event Time:
ACRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACRS alerts
High impacting Aclaris Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ACRS
News
- Aclaris Therapeutics files to sell 35.56M shares of common stock by selling shareholders [Seeking Alpha]Seeking Alpha
- Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare ConferenceGlobeNewswire
- Aclaris Therapeutics And 2 Other US Penny Stocks To Watch [Yahoo! Finance]Yahoo! Finance
ACRS
Earnings
- 11/6/24 - Miss
ACRS
Sec Filings
- 12/19/24 - Form S-3
- 12/12/24 - Form 4
- 12/6/24 - Form 4
- ACRS's page on the SEC website